FY2026 Earnings Forecast for Alector Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Alector to a loss of $0.03 per share from a projected loss of $0.93, while maintaining a Buy rating and an $8.00 price target.
• Alector’s latest quarterly results beat expectations, reporting a $0.21-per-share loss versus the $0.23 consensus estimate and revenue of $3.32 million compared with $1.71 million expected.
• Analyst sentiment remains mixed, with the stock carrying a consensus Hold rating and $4.00 price target; Alector shares recently traded at $1.91, while company insiders sold 111,303 shares worth about $295,633 over the past 90 days.

Alector, Inc. (NASDAQ:ALEC - Free Report) - Analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Alector in a research report issued on Wednesday, October 14th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.03) for the year, up from their prior estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $8.00 target price on the stock. The consensus estimate for Alector's current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Alector's Q4 2026 earnings at $0.62 EPS, FY2028 earnings at ($0.82) EPS and FY2030 earnings at ($0.75) EPS.

Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%. The business had revenue of $3.32 million during the quarter, compared to the consensus estimate of $1.71 million.

Other equities research analysts also recently issued research reports about the company. UBS Group reissued a "neutral" rating and set a $1.50 target price on shares of Alector in a report on Tuesday, October 6th. Weiss Ratings upgraded shares of Alector from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Finally, Morgan Stanley raised their price target on shares of Alector from $2.00 to $3.00 and gave the stock an "underweight" rating in a research report on Tuesday, October 6th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $4.00.

Alector Stock Performance

ALEC stock opened at $1.91 on Friday. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80. The business's fifty day moving average price is $2.11 and its two-hundred day moving average price is $2.03. Alector has a fifty-two week low of $1.09 and a fifty-two week high of $3.40.

Insider Buying and Selling at Alector

In other news, CEO Arnon Rosenthal sold 72,606 shares of the company's stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $193,131.96. Following the completion of the sale, the chief executive officer directly owned 2,294,600 shares in the company, valued at approximately $6,103,636. This represents a 3.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Neil Berkley sold 29,251 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $77,807.66. Following the sale, the chief financial officer directly owned 350,649 shares in the company, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 111,303 shares of company stock valued at $295,633 over the last ninety days. Insiders own 8.30% of the company's stock.

Hedge Funds Weigh In On Alector

Several hedge funds have recently bought and sold shares of ALEC. The Manufacturers Life Insurance Company acquired a new stake in shares of Alector during the 2nd quarter worth approximately $39,000. Diversified Trust Co lifted its stake in Alector by 83.6% during the first quarter. Diversified Trust Co now owns 25,895 shares of the company's stock worth $56,000 after purchasing an additional 11,793 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Alector during the second quarter worth $98,000. Sei Investments Co. lifted its stake in Alector by 218.9% during the first quarter. Sei Investments Co. now owns 53,846 shares of the company's stock worth $116,000 after purchasing an additional 36,962 shares during the last quarter. Finally, Ieq Capital LLC acquired a new stake in shares of Alector in the 2nd quarter valued at $122,000. 85.83% of the stock is owned by institutional investors.

Alector Company Profile

Alector, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer's disease, frontotemporal dementia and Parkinson's disease.

Alector's pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.